Skip to main content
Top
Published in: Annals of Surgical Oncology 9/2013

01-09-2013 | Urologic Oncology

Gleason 5+4 Has Worse Oncological and Pathological Outcomes Compared with Gleason 4+5: Significance of Gleason 5 Pattern

Authors: Sey Kiat Lim, MBBS, MRCS, MMed, FAMS, Kwang Hyun Kim, MD, Tae-Young Shin, MD, Byung Ha Chung, MD, PhD, Sung Joon Hong, MD, PhD, Young Deuk Choi, MD, PhD, Koon Ho Rha, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 9/2013

Login to get access

Abstract

Background

The purpose of this study was to evaluate the pathological and oncological significance of Gleason (G) 5 pattern in high-grade PCa after robotic-assisted radical prostatectomy (RARP).

Materials and Methods

From a cohort of 1,046 men, 159 post-RARP patients by a single surgeon with pathological G8 (N = 79) and G9 (N = 80) met our inclusion criteria. G9 cancers were sub-stratified into G4+5 (N = 58) and G5+4 (N = 22). Clinical and pathological outcomes were evaluated with the t test or Mann–Whitney U test for continuous variables and the Pearson χ 2 test for categorical variables. The Kaplan–Meier method was used to estimate the biochemical recurrence-free survival (BCRFS), and survival curves were compared using the log-rank test. Multivariate analysis was performed with Cox regression analysis.

Results

Baseline characteristics across all subgroups were similar except for number of positive cores on biopsy. There was a trend toward worse pathological and oncological outcomes in G9 cancers when compared with G8, although only tumor volume (TV), extracapsular extension (ECE) of tumor and lymph nodes involvement (LNI) achieved statistical significance. G4+5 PCa were statistically more likely to have ECE and a higher TV than G4+4 although the BCRFS were not significantly different. G5+4 cancers were associated with a significantly higher proportion of patients with LNI and had a statistically significant poorer BCRFS compared with G4+5 patients.

Conclusions

Oncological and pathological outcomes of G8 were significantly better than G9 and merited distinction between them. G5+4 harbors a much poorer BCRFS compared with G4+5, and hence we suggest considerations for immediate adjuvant treatments.
Literature
1.
go back to reference Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2003;169:157–63.PubMedCrossRef Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2003;169:157–63.PubMedCrossRef
2.
go back to reference Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin N Am. 2001;28:555–65.CrossRef Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin N Am. 2001;28:555–65.CrossRef
3.
go back to reference Donohue JF, Bianco Jr FJ, Kuroiwa K, Vickers AJ, Wheeler TM, Scardino PT, et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long term outcome and incidence of pathological downgrading. J Urol. 2006;176:991–5.PubMedCrossRef Donohue JF, Bianco Jr FJ, Kuroiwa K, Vickers AJ, Wheeler TM, Scardino PT, et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long term outcome and incidence of pathological downgrading. J Urol. 2006;176:991–5.PubMedCrossRef
4.
go back to reference Mian BM, Troncoso P, Okihara K, Bhadkamkar V, Johnston D, Reyes AO, et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol. 2002;167:1675–80.PubMedCrossRef Mian BM, Troncoso P, Okihara K, Bhadkamkar V, Johnston D, Reyes AO, et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol. 2002;167:1675–80.PubMedCrossRef
5.
go back to reference Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, et al. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int. 2012;110:1122–8.PubMedCrossRef Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, et al. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int. 2012;110:1122–8.PubMedCrossRef
6.
go back to reference Wambi CO, Siddiqui SA, Krane LS, Agarwal PK, Stricker HJ, Peabody JO. Early oncological outcomes of robot-assisted radical prostatectomy for high-grade prostate cancer. BJU Int. 2010;106:1739–45.PubMedCrossRef Wambi CO, Siddiqui SA, Krane LS, Agarwal PK, Stricker HJ, Peabody JO. Early oncological outcomes of robot-assisted radical prostatectomy for high-grade prostate cancer. BJU Int. 2010;106:1739–45.PubMedCrossRef
7.
go back to reference Tolonen TT, Kujala PM, Tammela TL, Tuominen VJ, Isola JJ, Visakorpi T. Overall and worst Gleason scores are equally good predictors of prostate cancer progression. BMC Urol. 2011;11:21–5.PubMedCrossRef Tolonen TT, Kujala PM, Tammela TL, Tuominen VJ, Isola JJ, Visakorpi T. Overall and worst Gleason scores are equally good predictors of prostate cancer progression. BMC Urol. 2011;11:21–5.PubMedCrossRef
8.
go back to reference Nanda A, Chen MH, Renshaw AA, D’Amico AV. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys. 2009;74:1419–23.PubMedCrossRef Nanda A, Chen MH, Renshaw AA, D’Amico AV. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys. 2009;74:1419–23.PubMedCrossRef
9.
go back to reference Alenda O, Ploussard G, Mouracade P, Xylinas E, de la Taille A, Allory Y, et al. Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors. World J Urol. 2011;29:671–6.PubMedCrossRef Alenda O, Ploussard G, Mouracade P, Xylinas E, de la Taille A, Allory Y, et al. Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors. World J Urol. 2011;29:671–6.PubMedCrossRef
10.
go back to reference McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer. 1990;66:1225–33.PubMedCrossRef McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer. 1990;66:1225–33.PubMedCrossRef
11.
go back to reference Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999;281:1395–400.PubMedCrossRef Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999;281:1395–400.PubMedCrossRef
12.
go back to reference Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. European Association of Urology guidelines on prostate cancer. http://www.uroweb.org. Accessed Oct 2012. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. European Association of Urology guidelines on prostate cancer. http://​www.​uroweb.​org. Accessed Oct 2012.
13.
15.
go back to reference Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG, Scardino PT, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institution pooled analysis. Eur Urol. 1997;32:385–90.PubMed Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG, Scardino PT, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institution pooled analysis. Eur Urol. 1997;32:385–90.PubMed
16.
go back to reference Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables [erratum published in J Urol. 2004;171:811]. Erratum. J Urol. 2002;167:117–22. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables [erratum published in J Urol. 2004;171:811]. Erratum. J Urol. 2002;167:117–22.
17.
go back to reference Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon D, et al. Role of radical prostatectomy in patients with prostate cancer of high Gleason score. Prostate. 1999;39:60–6.PubMedCrossRef Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon D, et al. Role of radical prostatectomy in patients with prostate cancer of high Gleason score. Prostate. 1999;39:60–6.PubMedCrossRef
18.
go back to reference Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, et al. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. BJU Int. 2013;111:723–30.PubMedCrossRef Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, et al. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. BJU Int. 2013;111:723–30.PubMedCrossRef
19.
go back to reference Serni S, Masieri L, Minervini A, Lapini A, Nesi G, Carini M. Cancer progression after anterograde radical prostatectomy for pathologic Gleason score 8 to 10 and influence of concomitant variables. Urology. 2006;67:373–8.PubMedCrossRef Serni S, Masieri L, Minervini A, Lapini A, Nesi G, Carini M. Cancer progression after anterograde radical prostatectomy for pathologic Gleason score 8 to 10 and influence of concomitant variables. Urology. 2006;67:373–8.PubMedCrossRef
20.
go back to reference Patel AA, Chen M, Renshaw AA, D’Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA. 2007;298:1533–8.PubMedCrossRef Patel AA, Chen M, Renshaw AA, D’Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA. 2007;298:1533–8.PubMedCrossRef
21.
go back to reference Pan CC, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens. Am J Surg Pathol. 2000;24:563–9.PubMedCrossRef Pan CC, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens. Am J Surg Pathol. 2000;24:563–9.PubMedCrossRef
22.
go back to reference Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrle R, et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol. 2005;23:2911–7.PubMedCrossRef Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrle R, et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol. 2005;23:2911–7.PubMedCrossRef
23.
go back to reference Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–9.PubMedCrossRef Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–9.PubMedCrossRef
24.
go back to reference Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet. 2005;366:572–8.PubMedCrossRef Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet. 2005;366:572–8.PubMedCrossRef
25.
go back to reference Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924–30.PubMedCrossRef Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924–30.PubMedCrossRef
26.
go back to reference Swanson GP, Thompson IM, Tangen C, Paradelo J, Canby-Hagino E, Crawford ED, et al. Update of SWOG 8794: adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival. Int J Radiat Oncol Biol Phys. 2008;72:S31–3.CrossRef Swanson GP, Thompson IM, Tangen C, Paradelo J, Canby-Hagino E, Crawford ED, et al. Update of SWOG 8794: adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival. Int J Radiat Oncol Biol Phys. 2008;72:S31–3.CrossRef
27.
go back to reference Gontero P, Spahn M, Tombal B, Bader P, Hsu CY, Marchioro G, et al. Is there a prostate-specific antigen upper limit for radical prostatectomy? BJU Int. 2011;108:1093–100.PubMedCrossRef Gontero P, Spahn M, Tombal B, Bader P, Hsu CY, Marchioro G, et al. Is there a prostate-specific antigen upper limit for radical prostatectomy? BJU Int. 2011;108:1093–100.PubMedCrossRef
28.
go back to reference Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys. 2000;48:1443–6.PubMedCrossRef Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys. 2000;48:1443–6.PubMedCrossRef
29.
go back to reference Kwan WB, Pickles T, Paltiel C, for the Prostate Cancer Outcomes Initiative. Does PSA failure in prostate cancer patients necessarily increase the risk of prostate cancer related death? An analysis in a cohort of 1790 patients. Proc Am Soc Clin Oncol. 2003;22:380–7. Abstract 1526. Kwan WB, Pickles T, Paltiel C, for the Prostate Cancer Outcomes Initiative. Does PSA failure in prostate cancer patients necessarily increase the risk of prostate cancer related death? An analysis in a cohort of 1790 patients. Proc Am Soc Clin Oncol. 2003;22:380–7. Abstract 1526.
Metadata
Title
Gleason 5+4 Has Worse Oncological and Pathological Outcomes Compared with Gleason 4+5: Significance of Gleason 5 Pattern
Authors
Sey Kiat Lim, MBBS, MRCS, MMed, FAMS
Kwang Hyun Kim, MD
Tae-Young Shin, MD
Byung Ha Chung, MD, PhD
Sung Joon Hong, MD, PhD
Young Deuk Choi, MD, PhD
Koon Ho Rha, MD, PhD, FACS
Publication date
01-09-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 9/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2996-4

Other articles of this Issue 9/2013

Annals of Surgical Oncology 9/2013 Go to the issue